<DOC>
	<DOC>NCT00117065</DOC>
	<brief_summary>The purpose of this study was to evaluate Aranesp速 administered subcutaneously (SC) to maintain hemoglobin (Hb) levels in renal transplant recipients.</brief_summary>
	<brief_title>Study of Transplant Related Anemia Treated With Aranesp速 (STRATA)</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>Subjects who are greater than 6 months postrenal transplant (living or cadaveric) Using adequate contraceptive precaution, if of childbearing potential Available for followup assessments and dosing visits Hb concentration less than 11.0 g/dL within 3 months of screening and a hemoglobin concentration less than 11.0 during the screening period Expected to initiate dialysis or transplantation or be scheduled for a kidney transplant within 6 months of study start, or have less than 1 year life expectancy Systemic hematologic disease, myeloma, hemolytic anemia, or malignancy (excluding basal cell carcinoma) Active systemic or chronic infection Uncontrolled hypertension defined as diastolic blood pressure greater than 110 mm Hg on 2 separate occasions during the 2 weeks prior to screening Known hypersensitivity to Aranesp速 or any of the product's excipients Disorders that compromise the ability of the subject to give written informed consent and/or to comply with study procedures Use of any erythropoietic protein or androgen therapy within the 12 weeks prior to screening Females who are pregnant or breastfeeding Currently enrolled in or received treatment in an investigational drug/device trial within the past 30 days Have previously been enrolled in this study Recent history (within 12 weeks prior to screening) of severe cardiovascular events, grand mal seizure, dialysis or major surgery Have received a red blood cell transfusion(s) within 8 weeks prior to screening, or currently have active bleeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Kidney transplant, Renal transplant</keyword>
	<keyword>Aranesp速, Darbepoetin alfa</keyword>
	<keyword>Amgen, Q2W dosing, Q4W dosing</keyword>
</DOC>